Literature DB >> 28861920

Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Kelvin César de Andrade1,2, Lisa Mirabello1, Douglas R Stewart1, Eric Karlins3, Roelof Koster4, Mingyi Wang3, Susan M Gapstur5, Mia M Gaudet5, Neal D Freedman6, Maria Teresa Landi7, Nathanaël Lemonnier8, Pierre Hainaut8, Sharon A Savage1, Maria Isabel Achatz1.   

Abstract

Li-Fraumeni syndrome (LFS) is an autosomal-dominant cancer predisposition disorder associated with pathogenic germline variants in TP53, with a high penetrance over an individual's lifetime. The actual population prevalence of pathogenic germline TP53 mutations is still unclear, most likely due to biased selection of cancer affected families. The aim of this study was to estimate the population prevalence of potentially pathogenic TP53 exonic variants in three sequencing databases, totaling 63,983 unrelated individuals. Potential pathogenicity was defined using an original algorithm combining bioinformatic prediction tools, suggested clinical significance, and functional data. We identified 34 different potentially pathogenic TP53 variants in 131 out of 63,983 individuals (0.2%). Twenty-eight (82%) of these variants fell within the DNA-binding domain of TP53, with an enrichment for specific variants that were not previously identified as LFS mutation hotspots, such as the p.R290H and p.N235S variants. Our findings reveal that the population prevalence of potentially pathogenic TP53 variants may be up to 10 times higher than previously estimated from family-based studies. These results point to the need for further studies aimed at evaluating cancer penetrance modifiers as well as the risk associated between cancer and rare TP53 variants. © Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Li-Fraumeni syndrome; TP53; cancer; genetic variation

Mesh:

Substances:

Year:  2017        PMID: 28861920      PMCID: PMC6858060          DOI: 10.1002/humu.23320

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  43 in total

1.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

2.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.

Authors:  F P Li; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1969-12       Impact factor: 13.506

3.  p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.

Authors:  S Quesnel; S Verselis; C Portwine; J Garber; M White; J Feunteun; D Malkin; F P Li
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

4.  Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

Authors:  Phuong L Mai; David Malkin; Judy E Garber; Joshua D Schiffman; Jeffrey N Weitzel; Louise C Strong; Oliver Wyss; Luana Locke; Von Means; Maria Isabel Achatz; Pierre Hainaut; Thierry Frebourg; D Gareth Evans; Eveline Bleiker; Andrea Patenaude; Katherine Schneider; Benjamin Wilfond; June A Peters; Paul M Hwang; James Ford; Uri Tabori; Simona Ognjanovic; Phillip A Dennis; Ingrid M Wentzensen; Mark H Greene; Joseph F Fraumeni; Sharon A Savage
Journal:  Cancer Genet       Date:  2012-08-29

Review 5.  Germline mutations in the TP53 gene.

Authors:  R A Eeles
Journal:  Cancer Surv       Date:  1995

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 7.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

9.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

Authors:  J M Birch; A L Hartley; K J Tricker; J Prosser; A Condie; A M Kelsey; M Harris; P H Jones; A Binchy; D Crowther
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer.

Authors:  Maria Teresa Landi; Dario Consonni; Melissa Rotunno; Andrew W Bergen; Alisa M Goldstein; Jay H Lubin; Lynn Goldin; Michael Alavanja; Glen Morgan; Amy F Subar; Ilona Linnoila; Fabrizio Previdi; Massimo Corno; Maurizia Rubagotti; Barbara Marinelli; Benedetta Albetti; Antonio Colombi; Margaret Tucker; Sholom Wacholder; Angela C Pesatori; Neil E Caporaso; Pier Alberto Bertazzi
Journal:  BMC Public Health       Date:  2008-06-06       Impact factor: 3.295

View more
  18 in total

1.  Use of Big Data to Estimate Prevalence of Defective DNA Repair Variants in the US Population.

Authors:  Jennifer Pugh; Sikandar G Khan; Deborah Tamura; Alisa M Goldstein; Maria Teresa Landi; John J DiGiovanna; Kenneth H Kraemer
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.

Authors:  Matthew B Lanktree; Amirreza Haghighi; Elsa Guiard; Ioan-Andrei Iliuta; Xuewen Song; Peter C Harris; Andrew D Paterson; York Pei
Journal:  J Am Soc Nephrol       Date:  2018-08-22       Impact factor: 10.121

3.  Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks.

Authors:  Hormuzd A Katki; Mark H Greene; Maria Isabel Achatz
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

4.  Population Testing for High Penetrance Genes: Are We There Yet?

Authors:  Nicolas Wentzensen; Christine D Berg
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

5.  A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.

Authors:  Ana F Best; Margaret A Tucker; Megan N Frone; Mark H Greene; June A Peters; Hormuzd A Katki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-28       Impact factor: 4.254

6.  Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk.

Authors:  Chenan Zhang; Joseph L Wiemels; Helen M Hansen; Julio Gonzalez-Maya; Alyson A Endicott; Adam J de Smith; Ivan V Smirnov; John S Witte; Libby M Morimoto; Catherine Metayer; Kyle M Walsh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

7.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

Review 8.  Cancer genetics, precision prevention and a call to action.

Authors:  Clare Turnbull; Amit Sud; Richard S Houlston
Journal:  Nat Genet       Date:  2018-08-29       Impact factor: 38.330

9.  Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.

Authors:  Flora Doffe; Vincent Carbonnier; Manon Tissier; Bernard Leroy; Isabelle Martins; Johanna S M Mattsson; Patrick Micke; Sarka Pavlova; Sarka Pospisilova; Jana Smardova; Andreas C Joerger; Klas G Wiman; Guido Kroemer; Thierry Soussi
Journal:  Cell Death Differ       Date:  2020-11-30       Impact factor: 15.828

10.  Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.

Authors:  Cristina Fortuno; Kristy Lee; Magali Olivier; Tina Pesaran; Phuong L Mai; Kelvin C de Andrade; Laura D Attardi; Stephanie Crowley; D Gareth Evans; Bing-Jian Feng; Ann K M Foreman; Megan N Frone; Robert Huether; Paul A James; Kelly McGoldrick; Jessica Mester; Bryce A Seifert; Thomas P Slavin; Leora Witkowski; Liying Zhang; Sharon E Plon; Amanda B Spurdle; Sharon A Savage
Journal:  Hum Mutat       Date:  2020-12-25       Impact factor: 4.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.